N/A N=90 pLatelEts And MigRaine iN patEnt foRamen Ovale
Platelet Aggregation, Spontaneous · Migraine With Aura · Patent Foramen Ovale
Primary: Change in Migraine Characteristics — 43; 2; 17 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=50 Trial of Comprehensive Migraine Intervention
Migraine
Primary: Migraine Functional Impairment as Measured by Score on the Headache Impact Test 6 (HIT6) Scale — 59; 56 units on a scale
N/A N=18 Clinical Decision Support for Patient Migraine Management
Migraine
Primary: Adherence to Acute Migraine Management Strategies: Treat Early — 0; 2 Participants
Phase 2 N=31 Treatment of Acute Migraine Headache in Children
Migrainous Headache
Primary: The Number of Subjects With a Numeric Rating Scale Score (NRS) of Zero at Two Hours. — 5; 12 participants — p=0.03
Phase 3 N=157 MLD10 in the Prevention of Migraine in Adults
Migraine
Primary: Migraine Headache Days — 7.12; 6.92; 5.53; 4.79 Days
N/A N=60 Bronx MBCT-Migraine
Migraine
Primary: Proportion of People With "Severe" Scores on the Migraine Disability Assessment — 77.4; 89.7; 58.1; 75.9 percentage of participants — p=.027
Phase 3 N=205 Headache in the Emergency Department (ED) - A Multi-Center Research Network to Optimize the ED Treatment of Migraines
Migraine
Primary: Persistent Headache Pain Free at 24 Hours — 26; 19 Participants
N/A N=16,789 Chronic Migraine Epidemiology and Outcomes Study
Migraine Disorders
Primary: Percentage of Participants With Episodic Migraine (EM) or Chronic Migraine (CM) — 91.2; 8.8 percentage of participants
Phase 4 N=220 Corticosteroids for Acute Migraine in the Emergency Department
Migraine
Primary: Headache Days as Self-reported by Participants — 3.0; 3.3 days
Phase 3 N=473 Treatment of Multiple Attacks of Acute Migraine (0462-025)
Migraine Headache
Primary: Pain Relief at 2 Hours During the First Migraine Attack Period — 246; 30; 74; 52 participants
N/A N=100 A Non-Invasive Neuromodulation Device for Treatment of Migraine Headache
Migraine Headache, Episodic
Primary: Change in Number of Monthly Migraine Headache Days — -3.5; -1.1 migraine days
N/A N=568 Study of Two Digital Therapeutics for the Prevention of Episodic Migraine
Migraine · Episodic Migraine · Headache
Primary: Change in MMD (Monthly Migraine Days) — -3.04; -2.14 migraine days per month
N/A N=20 Music Intervention on Migraine Headaches
Migraine Headache
Primary: Frequency of Migraine Attacks (Number of Days Per Month) — 8.45; 5.65 Number of migraine per months — p=0.012
N/A N=31 Comorbidities Associated With Migraine and Patent Foramen Ovale (CAMP)
Migraine With Aura · Patent Foramen Ovale
Primary: Embolic Tracks
N/A N=89 Mindfulness and Mechanisms of Pain Processing in Adults With Migraines
Migraine
Primary: Change in Frequency of Migraine Days Per Month From Baseline — -1.6; -2.0 number of days
N/A N=140 Treatment for Migraines With an Implantable Device
Migraine
Primary: Migraine Frequency at 12 Weeks — -5.5; -3.9 days
Phase 2 N=16 Treatment for Migraine and Mood (Team-M)
Migraine · Depression
Primary: Treatment Session Adherence Rate — 7.88; 8 Number of sessions attended
N/A N=252 Evaluation of a Novel Device for Treatment of Migraine Headache
Migraine Without Aura · Migraine With Aura
Primary: Percentage of Participants With Reduction of Migraine Headache at 2 Hours Post Treatment — 66; 40 Participants
Phase 4 N=79 Treatment of Insomnia in Migraineurs
Insomnia · Migraine
Primary: Total Sleep Time — 5.4; 5.5; 6.3; 6.1 hours — p=0.33
N/A N=24 The Effect of Different Exercise Types on Migraine Frequency in Individuals With Migraine
Migraine · Chronic Migraine
Primary: Change in the Number of Days With Migraine (in Migraine Frequency) — 9.9; 12.4; 11.8; 6.3 days/month — p=0.001
N/A N=87 Chordate System Prophylactic Migraine Clinical Investigation
Migraine
Primary: Change From Baseline in Number of Migraine Days Per Four Weeks During the Three Months Post Treatment Investigation Duration — -1.5; -1.3 Migraine days/four weeks…
Phase 4 N=232 Drug and Non-Drug Treatment Of Severe Migraine
Migraine Headache
Primary: Change in Number of Migraine Episodes Per 30 Days at Month 10. — -2.1; -2.1; -2.2; -3.3 Number of Migraine episodes — p=< .01
Phase 2 N=26 Bringing Relief to Adolescents Naturally Using Melatonin for Migraine
Migraine in Adolescents
Primary: Number of Migraine/Migrainous Days Per 28 Day Period — 3.6; 4.9 days
Phase 3 N=2,231 Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
Acute Migraine
Primary: Percentage of Participants Who Are Headache Pain Free — 28.2; 32.2; 15.3 percentage of participants — p=<0.001
Phase 4 N=78 Treatment of Tinnitus With Migraine Medications
Tinnitus, Subjective · Tinnitus
Primary: Tinnitus Functional Index (TFI) — -12.1; -12.4; -6.0 scores on a scale
Phase 3 N=34 Metformin for the Prevention of Episodic Migraine (MPEM)
Migraine
Primary: Headache Days — 23.64; 24.33 Days — p=0.83
N/A N=136 Vagus Nerve Stimulation and Stress Reduction Training for Migraine
Migraine
Primary: Brain Activity Changes in Migraine Patients in Response to Treatment — -0.249; 0.679; 0.680; 1.06 Log ratio % signal change (Insula/Sp5)
N/A N=41 Effects of Lifestyle Modification on Vestibular Migraine
Vestibular Migraine
Primary: Headache Disability Inventory (HDI) — 14.3 score on a scale — p=<.0001
N/A N=45 Brief Behavioral Intervention for Comorbid Migraine and Depression
Migraine · Depression
Primary: Mean Change in Hamilton Depression Rating Scale (HAM-D) From Baseline to 12 Week Follow-up — -15.1; -4.3 units on a scale
N/A N=459 A Retrospective Chart Review to Evaluate Diagnosis and Treatment of Chronic Migraine and Headache
Migraine Disorders · Headache
Primary: Presence or Absence of Prophylactic Medication for Headache/Migraine — 166; 227; 18; 48 Participants